Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials.
Litwin SE, Komtebedde J, Borlaug BA, Kaye DM, Hasenfuβ G, Kawash R, Hoendermis E, Hummel SL, Cikes M, Gustafsson F, Chung ES, Mohan RC, Sverdlov AL, Swarup V, Winkler S, Hayward CS, Bergmann MW, Bugger H, McKenzie S, Nair A, Rieth A, Burkhoff D, Cutlip DE, Solomon SD, van Veldhuisen DJ, Leon MB, Shah SJ. Litwin SE, et al. Among authors: kaye dm. Am Heart J. 2024 Dec;278:106-116. doi: 10.1016/j.ahj.2024.08.014. Epub 2024 Sep 3. Am Heart J. 2024. PMID: 39237070 Clinical Trial.
Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES).
Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M; SOCRATES Investigators and Coordinators. Pieske B, et al. Eur J Heart Fail. 2014 Sep;16(9):1026-38. doi: 10.1002/ejhf.135. Epub 2014 Jul 24. Eur J Heart Fail. 2014. PMID: 25056511 Free article. Clinical Trial.
Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Gheorghiade M, et al. JAMA. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. JAMA. 2015. PMID: 26547357 Clinical Trial.
A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial.
Hasenfuß G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F, Malek F, Van der Heyden J, Lang I, Petrie MC, Cleland JG, Leon M, Kaye DM; REDUCE LAP-HF study investigators. Hasenfuß G, et al. Among authors: kaye dm. Lancet. 2016 Mar 26;387(10025):1298-304. doi: 10.1016/S0140-6736(16)00704-2. Lancet. 2016. PMID: 27025436 Free article. Clinical Trial.
2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.
Gustafsson F, Petrie MC, Komtebedde J, Swarup V, Winkler S, Hasenfuß G, Borlaug BA, Mohan RC, Flaherty JD, Sverdlov AL, Fail PS, Chung ES, Lurz P, Lilly S, Kaye DM, Cleland JGF, Cikes M, Leon MB, Cutlip DE, van Veldhuisen DJ, Solomon SD, Shah SJ. Gustafsson F, et al. Among authors: kaye dm. JACC Heart Fail. 2024 Aug;12(8):1425-1438. doi: 10.1016/j.jchf.2024.04.011. Epub 2024 Jun 26. JACC Heart Fail. 2024. PMID: 38934964 Clinical Trial.
Early Use of Aspirin for Coronary Allograft Prophylaxis in Heart Transplant Recipients.
Kessler Iglesias C, Bloom JE, Xiao X, Moskovitch J, Eckford H, Offen S, Kotlyar E, Keogh A, Jabbour A, Bergin P, Leet A, Hare JL, Taylor AJ, Hayward CS, Jansz P, Kaye DM, Macdonald PS, Muthiah K. Kessler Iglesias C, et al. Among authors: kaye dm. Transplantation. 2024 Jul 18. doi: 10.1097/TP.0000000000005131. Online ahead of print. Transplantation. 2024. PMID: 39020464
Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival.
Bloom JE, Vogrin S, Reid CM, Ajani AE, Clark DJ, Freeman M, Hiew C, Brennan A, Dinh D, Williams-Spence J, Dawson LP, Noaman S, Chew DP, Oqueli E, Cox N, McGiffin D, Marasco S, Skillington P, Royse A, Stub D, Kaye DM, Chan W. Bloom JE, et al. Among authors: kaye dm. Eur Heart J. 2024 Oct 29:ehae672. doi: 10.1093/eurheartj/ehae672. Online ahead of print. Eur Heart J. 2024. PMID: 39471463
Leveraging metabolism for better outcomes in heart failure.
Ng YH, Koay YC, Marques FZ, Kaye DM, O'Sullivan JF. Ng YH, et al. Among authors: kaye dm. Cardiovasc Res. 2024 Oct 1:cvae216. doi: 10.1093/cvr/cvae216. Online ahead of print. Cardiovasc Res. 2024. PMID: 39351766
The Efficacy of Risk Factor Modification Compared to NAD+ Repletion in Diastolic Heart Failure.
Koay YC, Liu RP, McIntosh B, Vigder N, Lauren S, Bai AY, Tomita S, Li D, Harney D, Hunter B, Zhang Y, Yang J, Bannon P, Philp A, Philp A, Kaye DM, Larance M, Lal S, O'Sullivan JF. Koay YC, et al. Among authors: kaye dm. JACC Basic Transl Sci. 2024 Mar 20;9(6):733-750. doi: 10.1016/j.jacbts.2024.01.011. eCollection 2024 Jun. JACC Basic Transl Sci. 2024. PMID: 39070276 Free PMC article.
420 results